The EPS projection of Cardiome Pharma Corporation (NASDAQ:CRME) for quarter ended 2016-09-30 is $-0.18. Last week, the projection for EPS was $-0.18 against target of $-0.18, a month earlier. While 2-months ago, this projection was $-0.18 versus forecast of $-0.18a quarter months earlier, posting a deviation of 0%.
Cardiome Pharma Corporation (NASDAQ:CRME) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 1.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 1, and 1, correspondingly.
The per-share earnings downgrade for Cardiome Pharma Corporation (NASDAQ:CRME) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 0, and 1, in that order.
Cardiome Pharma Corporation (NASDAQ:CRME) EPS target was $-0.18 for the quarter closed 1. It was based on 2 calls. As on 2016-05-13 the EPS was $-0.06. The change was $0.12, posting a deviation of 66.67%. The price projections gave a standard deviation of 0.06.
Quarterly Sales Estimates
Cardiome Pharma Corporation (NASDAQ:CRME) sales prediction for the fiscal 2016 stands at $8.41 and the median estimate is at $7.72. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $10.41 while the lowest target is $7.1 showing standard deviation of 1.759%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of -1.637%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...